Vahlensieck W, Wegner G, Lehmann H D, Franzen G, Steffens L, Wählby S
Urol Res. 1985;13(5):209-12. doi: 10.1007/BF00261577.
Ninety-five patients with prostatic carcinoma, stages A-D and of all histological grades were randomized between a continuous and an intermittent treatment regimen of Estracyt (estramustine phosphate). 77 patients were evaluated (46 with continuous and 31 with intermittent therapy). Remissions were seen in 13 (28%) and (13%), respectively. Stable disease was recorded in 30 (65%) and 24 (77%), respectively. Progression experienced 3 (6%) and 3 (10%) respectively. 19% were unable to continue therapy due to intolerable gastrointestinal side effects (7 patients receiving continuous and 8 patients receiving intermittent therapy).
95例A - D期、具有所有组织学分级的前列腺癌患者被随机分为雌氮芥磷酸酯（癌腺治）持续治疗方案组和间歇治疗方案组。对77例患者进行了评估（46例接受持续治疗，31例接受间歇治疗）。分别有13例（28%）和4例（13%）出现缓解。疾病稳定分别记录为30例（65%）和24例（77%）。进展分别为3例（6%）和3例（10%）。19%的患者因无法耐受的胃肠道副作用而无法继续治疗（7例接受持续治疗，8例接受间歇治疗）。
